Universität zu Köln

Ohlmann, Carsten-Henning, Markert, Eva, Gerharz, Michael, Dienes, Hans-Peter, Stoeckle, Michael, Engelmann, Udo and Heidenreich, Axel (2011). Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer. Urol. Oncol.-Semin. Orig. Investig., 29 (6). S. 664 - 670. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1873-2496

Full text not available from this repository.

Abstract

Objectives: In order to improve the efficacy of targeted therapy trials, the expression profiles of several molecular markers that are potential candidates for targeted therapy were analyzed in patients with progressive castration-resistant prostate cancer. Methods and materials: Paraffin-embedded samples of tumor tissue from 51 patients obtained from biopsies of metastases or remaining prostates were analyzed immunohistochemically for the expression of EGFR, PDGFR beta, Her-2/neu, c-Kit, and VEGF. Staining was analyzed according to the percentage of positively stained tumor cells and the intensity of staining. Results: According to the different cut-off values of 10%, 30%, 50%, or 70% for the percentage of positively stained cells, different rates of expression were found. Expression rates ranged from 30.6% to 61.2% for EGFR, from 34.7% to 57.1% for PDGFR beta, from 9.6% to 28.8% for Her-2/neu, from 12.5% to 22.4% for c-Kit, and from 51.1% to 74.5% for VEGF. Defining positive expression as >= 30% positively stained tumor cells, with an intensity of staining of >= 2+, resulted in positive expression of EGFR in 38.8%, PDGFR beta in 24.5%, Her-2/neu in 13.5%, c-Kit in 6.4%, and VEGF in 44.7% of the patients. Conclusions: Our results demonstrate simultaneous expression of several markers in castration-resistant prostate cancer tissue. Translation of the results into modern, multi-arm clinical trial designs will improve the efficacy of recruiting and obtaining results, compared with multiple double-arm trials. (C) 2011 Elsevier Inc. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Ohlmann, Carsten-Henning UNSPECIFIED UNSPECIFIED UNSPECIFIED Markert, Eva UNSPECIFIED UNSPECIFIED UNSPECIFIED Gerharz, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Dienes, Hans-Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Stoeckle, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Engelmann, Udo UNSPECIFIED UNSPECIFIED UNSPECIFIED Heidenreich, Axel UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-485953
DOI:	10.1016/j.urolonc.2009.09.010
Journal or Publication Title:	Urol. Oncol.-Semin. Orig. Investig.
Volume:	29
Number:	6
Page Range:	S. 664 - 670
Date:	2011
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1873-2496
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; ANDROGEN-INDEPENDENCE; IMATINIB MESYLATE; CLINICAL-TRIALS; CELL CARCINOMA; LOCAL THERAPY; EXPRESSION; PROGRESSION; TRASTUZUMAB Multiple languages Oncology; Urology & Nephrology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/48595